Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

NCT04668495 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2021-09-14

No results posted yet for this study

Summary

This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.

Conditions

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    collaborator INDUSTRY
  • University of Florida

    lead OTHER

Principal Investigators

  • Dominick Angiolillo, MD, PhD · Professor of Medicine

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2021-04-04
Completion
2021-07-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04668495 on ClinicalTrials.gov